I have never said that any potential discussions with the FDA are negative. I have never even implied that. I hope that they work out in our favor and again, I think the drug will get approved. I have concerns about whether the patient population will be large enough to support the current market cap, but I believe that DCVAX-L works for some percentage of nGBM and rGBM patients...I hope it's enough to justify broad approval.
I see that you've jumped on an admission of mine that not every single biotech I follow was "unique," in the way that NWBO is. I already said that, but good for you for pointing it out and acting like I tried to compare those examples with what is going on with DCVAX-L. I award you 10 internet points and 5 more for anyone else who chimes in with a cheerleading post and jumps on this particular bandwagon. Really, you should know better.
As for the late filings, I know the count is real because I counted them all. Call it professional curiosity...maybe I'll write an article about it someday. In my world, if you file an NT 10-Q or K for any reason other than an ongoing investigation (audit committee driven or SEC), then it's late. That's how the exchanges look at it, and that's how other professionals look at, and even though the SEC may not penalize them, I'm sure they would think the same thing: that's it's horribly sloppy and embarrassing. And I can comment on the S-3 eligibility, as I did. Because it is a fact. I don't care if you believe me or not. And hey, if they don't need to issue equity anytime soon, then it doesn't really matter. They aren't seeking to increase the authorized share amount, so maybe they are going to sell themselves right after TLD. But if they DO need capital, then they've pushed themselves back at least a couple more months because now they will have to go through the S-1 process AND have a special meeting...this is CRAZY, even if they plan to sell, because until they've signed a definitive agreement, they should be ready to hit the ground running post-TLD. But this kind of self-inflicted and unnecessary delay would be par for the course for NWBO.
I agree that it is possible that the "delay" will end up not being a delay at all, as MI so graciously shared an example of yesterday. However, the journal publication stuff is nonsense, in my opinion. It doesn't further the goal of gaining regulatory approval and it doesn't further the goal of commercialization. The idea of waiting on a journal only serves the purpose of giving them a plausible explanation of the delay. I have a problem with this, because I feel like it is misleading. You are obviously free to believe what you want to believe. I see a history of statements from the company that turned out not to be true and I believe this is just another one in a long line...I just hope that the ends justify the means at the end of the day.
